SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.71 CNY | +2.24% |
|
+5.33% | -5.27% |
| Sales 2024 * | 45.05B 6.23B | Sales 2025 * | 50.8B 7.03B | Capitalization | 56.6B 7.83B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.34B 462M | Net income 2025 * | 4.28B 592M | EV / Sales 2024 * | 1.6 x |
| Net Debt 2024 * | 15.69B 2.17B | Net Debt 2025 * | 17.77B 2.46B | EV / Sales 2025 * | 1.46 x |
| P/E ratio 2024 * |
18.8
x | P/E ratio 2025 * |
14.6
x | Employees | 40,370 |
| Yield 2024 * |
1.76% | Yield 2025 * |
2.07% | Free-Float | 63.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.24% | ||
| 1 week | +5.33% | ||
| Current month | +2.77% | ||
| 1 month | +2.51% | ||
| 3 months | +2.33% | ||
| 6 months | -15.56% | ||
| Current year | -5.27% |
1 week
22.46
23.91
1 month
22.2523.91
Current year
20.3825.89
1 year
20.3832.74
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 2 M€ | -14.86% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-28 | 23.71 | +2.24% | 17 613 850 |
| 24-04-26 | 23.19 | +1.35% | 11,252,670 |
| 24-04-25 | 22.88 | +0.66% | 8,754,328 |
| 24-04-24 | 22.73 | -0.09% | 5,584,819 |
| 24-04-23 | 22.75 | +0.04% | 7,525,549 |
End-of-day quote Shanghai S.E., April 28, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.71
CNY
Average target price
29.75
CNY
Spread / Average Target
+25.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.27% | 7.65B | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
- Stock Market
- Equities
- 600196 Stock
